Bayer: study results in heart failure

(CercleFinance.com) - The group announced this morning that finerenone met the primary endpoint of the phase III FINEARTS-HF cardiovascular outcomes study in heart failure patients with a slightly reduced or preserved ejection fraction.


Heart failure (HF) is a chronic disease characterised by the progressive decline in the heart's ability to fill and pump enough blood to meet the body's needs. It affects over 60 million people worldwide. Around half of these patients suffer from CHF with an LVEF of ≥40%.

Finerenone significantly reduced the composite number of cardiovascular deaths and total heart failure (first and recurrent) compared with placebo in addition to usual treatment.

Finerenone, a selective non-steroidal mineralocorticoid receptor (MR) antagonist, is the first MR antagonist to demonstrate definitive cardiovascular benefits in a phase III study in patients with CHF with LVEF ≥40%.

Clinical data from FINEARTS-HF will be presented at the ESC Congress 2024. Bayer will discuss the data with health authorities regarding the submission of a marketing authorisation application.

With limited options currently available for patients with this common form of heart failure with slightly reduced or preserved ejection fraction, this news is extremely important for patients and the clinical community, Bayer said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.